Clinical Trials Directory

Trials / Completed

CompletedNCT03778307

Key Dimensions of PTSD and ED

Key Dimensions of Post-traumatic Stress Disorder (PTSD) and Endothelial Dysfunction (ED)

Status
Completed
Phase
Study type
Observational
Enrollment
168 (actual)
Sponsor
University of California, Los Angeles · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will test whether endothelial dysfunction could be the early subclinical mechanism by which posttraumatic stress disorder (PTSD) increases cardiovascular disease (CVD) risk, and whether posttraumatic fear-a key component of PTSD-or another PTSD dimension could be the target to offset that risk. The results of this study may help trauma-exposed individuals who are at risk of having CVD events.

Detailed description

Posttraumatic stress disorder (PTSD) increases risk of incident cardiovascular disease (CVD) by 25-50%. Most individuals (50-90%) experience a traumatic event in their lifetime, and PTSD is the fifth most common psychiatric disorder. Experts have now called for increased CVD surveillance after trauma and for PTSD treatment trials powered to reduce CVD risk. However, both CVD risk and PTSD are complex phenomena that likely interact in nuanced ways. This study will determine which PTSD dimension(s) contribute to endothelial dysfunction, one of the earliest modifiable precursors to CVD. The investigators will examine cross-sectional and longitudinal associations of PTSD and its underlying dimensions with functional and, secondarily, cellular measures of endothelial dysfunction (FMD and circulating endothelial cell-derived microparticles, respectively) in a community-dwelling sample of CVD-free adult men and women with a history of trauma (50% with current PTSD).

Conditions

Interventions

TypeNameDescription
BEHAVIORALPsychophysiological fear conditioning and extinction taskBehavioral task to assess psychophysiological measures of fear
BEHAVIORALEyetracking taskBehavioral task to assess dysphoria-relevant attention allocation

Timeline

Start date
2019-11-20
Primary completion
2025-06-30
Completion
2025-06-30
First posted
2018-12-19
Last updated
2026-01-26

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03778307. Inclusion in this directory is not an endorsement.